Alexion Pharmaceuticals, Inc. ($ALXN) Target: $118 Confident Investor Rating: Good

Company name Alexion Pharmaceuticals, Inc.
Stock ticker ALXN
Live stock price [stckqut]ALXN[/stckqut]
P/E compared to competitors Fair
MANAGEMENT EXECUTION
Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Poor
EBIT growth Good
ANALYSIS
Confident Investor Rating Good
Target stock price (TWCA growth scenario) $125.89
Target stock price (averages with growth) $204.31
Target stock price (averages with no growth) $126.37
Target stock price (manual assumptions) $114.35

“Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company,
which is engaged in the discovery, development and commercialization of
biologic therapeutic products aimed at treating patients with severe and
life-threatening disease states, including hematologic, kidney and
neurologic diseases, transplant rejection, cancer and autoimmune disorders.
Its marketed product Soliris (eculizumab) is a therapy approved for the
treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In
April 2009 and August 2009, the United States food and drug administration
(FDA) and the European Commission (E.C.), respectively, granted Soliris
orphan drug designation for the treatment of patients with atypical
Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island
manufacturing facility received regulatory approval from the E.C. for the
production of Soliris. ”

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.